NBQX (2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline) is an
antagonist of the
AMPA receptor.
NBQX blocks AMPA receptors in micromolar concentrations (~10–20 μM) and also blocks
kainate receptors. In experiments, it is used to counter
glutamateexcitotoxicity.[1] NBQX was found to have anticonvulsant activity in rodent seizure models.[2]
As the disodium salt, NBQX is soluble in water at high concentrations (at least up to 100 mM).
^Pitt, D.; Werner, P.; Raine, C. S. (2000). "Glutamate excitotoxicity in a model of multiple sclerosis". Nat Med.6 (1): 67–70.
^Yamaguchi, S.; Donevan, S.D.; Rogawski, M.A. (1993). Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res.15:179–184.
NBQX (2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline) is an
antagonist of the
AMPA receptor.
NBQX blocks AMPA receptors in micromolar concentrations (~10–20 μM) and also blocks
kainate receptors. In experiments, it is used to counter
glutamateexcitotoxicity.[1] NBQX was found to have anticonvulsant activity in rodent seizure models.[2]
As the disodium salt, NBQX is soluble in water at high concentrations (at least up to 100 mM).
^Pitt, D.; Werner, P.; Raine, C. S. (2000). "Glutamate excitotoxicity in a model of multiple sclerosis". Nat Med.6 (1): 67–70.
^Yamaguchi, S.; Donevan, S.D.; Rogawski, M.A. (1993). Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res.15:179–184.